Table No.
|
Table Title
|
Table 1.1-1
|
Patent information of aminopyralid in some countries/regions, as of July 2018
|
Table 1.1-2
|
Registration information of aminopyralid in China, as of July 2018
|
Table 1.1-3
|
Registration information of aminopyralid in Finland, as of July 2018
|
Table 1.1-4
|
Registration information of aminopyralid in Denmark, as of July 2018
|
Table 1.1-5
|
Registration information of aminopyralid in Canada, as of July 2018
|
Table 1.1-6
|
Registration information of aminopyralid in France, as of July 2018
|
Table 1.1-7
|
Registration information of aminopyralid in Uruguay, as of July 2018
|
Table 1.1-8
|
Registration information of aminopyralid in Australia, as of July 2018
|
Table 1.1-9
|
Registration information of aminopyralid in Switzerland, as of July 2018
|
Table 1.1-10
|
Registration information of aminopyralid in Argentina, as of July 2018
|
Table 1.1-11
|
Registration information of aminopyralid in South Africa, as of July 2018
|
Table 1.1-12
|
Registration information of aminopyralid in Belgium, as of July 2018
|
Table 1.1-13
|
Registration information of aminopyralid in Greece, as of July 2018
|
Table 1.2-1
|
Patent information of flucetosulfuron in some countries/regions, as of July 2018
|
Table 1.2-2
|
Registration information of flucetosulfuron in China, as of July 2018
|
Table 1.3-1
|
Patent information of flufenpyr-ethyl in some countries/regions, as of July 2018
|
Table 1.4-1
|
Patent information of metamifop in some countries/regions, as of July 2018
|
Table 1.4-2
|
Registration information of metamifop in China, as of July 2018
|
Table 1.4-3
|
Registration information of metamifop in Uruguay, as of July 2018
|
Table 1.5-1
|
Patent information of orthosulfamuron in some countries/regions, as of July 2018
|
Table 1.5-2
|
Registration information of orthosulfamuron in China, as of July 2018
|
Table 1.5-3
|
Registration information of orthosulfamuron in Brazil, as of July 2018
|
Table 1.6-1
|
Patent information of pinoxaden in some countries/regions, as of July 2018
|
Table 1.6-2
|
Registration information of pinoxaden in Argentina, as of July 2018
|
Table 1.6-3
|
Registration information of pinoxaden in South Africa, as of July 2018
|
Table 1.6-4
|
Registration information of pinoxaden in Australia, as of July 2018
|
Table 1.6-5
|
Registration information of pinoxaden in Belgium, as of July 2018
|
Table 1.6-6
|
Registration information of pinoxaden in Canada, as of July 2018
|
Table 1.6-7
|
Registration information of pinoxaden in Chile, as of July 2018
|
Table 1.6-8
|
Registration information of pinoxaden in China, as of July 2018
|
Table 1.6-9
|
Registration information of pinoxaden in Finland, as of July 2018
|
Table 1.6-10
|
Registration information of pinoxaden in France, as of July 2018
|
Table 1.6-11
|
Registration information of pinoxaden in Greece, as of July 2018
|
Table 1.6-12
|
Registration information of pinoxaden in the Netherlands, as of July 2018
|
Table 1.6-13
|
Registration information of pinoxaden in Switzerland, as of July 2018
|
Table 1.6-14
|
Registration information of pinoxaden in Uruguay, as of July 2018
|
Table 1.7-1
|
Patent information of pyrasulfotole in some countries/regions, as of July 2018
|
Table 1.7-2
|
Registration information of pyrasulfotole in Canada, as of July 2018
|
Table 1.7-3
|
Registration information of pyrasulfotole in Australia, as of July 2018
|
Table 1.7-4
|
Registration information of pyrasulfotole in South Africa, as of July 2018
|
Table 1.8-1
|
Patent information of pyroxasulfone in some countries/regions, as of July 2018
|
Table 1.8-2
|
Registration information of pyroxasulfone in Canada, as of July 2018
|
Table 1.8-3
|
Registration information of pyroxasulfone in Australia, as of July 2018
|
Table 1.8-4
|
Registration information of pyroxasulfone in South Africa, as of July 2018
|
Table 1.9-1
|
Patent information of pyroxsulam in some countries/regions, as of July 2018
|
Table 1.9-2
|
Registration information of pyroxsulam in China, as of July 2018
|
Table 1.9-3
|
Registration information of pyroxsulam in Belgium, as of July 2018
|
Table 1.9-4
|
Registration information of pyroxsulam in Brazil, as of July 2018
|
Table 1.9-5
|
Registration information of pyroxsulam in Canada, as of July 2018
|
Table 1.9-6
|
Registration information of pyroxsulam in France, as of July 2018
|
Table 1.9-7
|
Registration information of pyroxsulam in the Netherlands, as of July 2018
|
Table 1.9-8
|
Registration information of pyroxsulam in Australia, as of July 2018
|
Table 1.9-9
|
Registration information of pyroxsulam in Switzerland, as of July 2018
|
Table 1.9-10
|
Registration information of pyroxsulam in Denmark, as of July 2018
|
Table 1.9-11
|
Registration information of pyroxsulam in Finland, as of July 2018
|
Table 1.9-12
|
Registration information of pyroxsulam in Greece, as of July 2018
|
Table 1.9-13
|
Registration information of pyroxsulam in South Africa, as of July 2018
|
Table 1.10-1
|
Patent information of saflufenacil in some countries/regions, as of July 2018
|
Table 1.10-2
|
Registration information of saflufenacil in China, as of July 2018
|
Table 1.10-3
|
Registration information of saflufenacil in Brazil, as of July 2018
|
Table 1.10-4
|
Registration information of saflufenacil in Canada, as of July 2018
|
Table 1.10-5
|
Registration information of saflufenacil in Uruguay, as of July 2018
|
Table 1.10-6
|
Registration information of saflufenacil in Australia, as of July 2018
|
Table 1.10-7
|
Registration information of saflufenacil in Chile, as of July 2018
|
Table 1.10-8
|
Registration information of saflufenacil in Argentina, as of July 2018
|
Table 1.11-1
|
Patent information of tembotrione in some countries/regions, as of July 2018
|
Table 1.11-2
|
Registration information of tembotrione in Belgium, as of July 2018
|
Table 1.11-3
|
Registration information of tembotrione in South Africa, as of July 2018
|
Table 1.11-4
|
Registration information of tembotrione in Canada, as of July 2018
|
Table 1.11-5
|
Registration information of tembotrione in Chile, as of July 2018
|
Table 1.11-6
|
Registration information of tembotrione in France, as of July 2018
|
Table 1.11-7
|
Registration information of tembotrione in the Netherlands, as of July 2018
|
Table 1.11-8
|
Registration information of tembotrione in Switzerland, as of July 2018
|
Table 1.11-9
|
Registration information of tembotrione in Greece, as of July 2018
|
Table 1.12-1
|
Patent information of thiencarbazone-methyl in some countries/regions, as of July 2018
|
Table 1.12-2
|
Registration information of thiencarbazone-methyl in Belgium, as of July 2018
|
Table 1.12-3
|
Registration information of thiencarbazone-methyl in Canada, as of July 2018
|
Table 1.12-4
|
Registration information of thiencarbazone-methyl in France, as of July 2018
|
Table 1.12-5
|
Registration information of thiencarbazone-methyl in the Netherlands, as of July 2018
|
Table 1.12-6
|
Registration information of thiencarbazone-methyl in Uruguay, as of July 2018
|
Table 1.12-7
|
Registration information of thiencarbazone-methyl in China, as of July 2018
|
Table 1.12-8
|
Registration information of thiencarbazone-methyl in Denmark, as of July 2018
|
Table 1.13-1
|
Patent information of topramezone in some countries/regions, as of July 2018
|
Table 1.13-2
|
Registration information of topramezone in Argentina, as of July 2018
|
Table 1.13-3
|
Registration information of topramezone in South Africa, as of July 2018
|
Table 1.13-4
|
Registration information of topramezone in Canada, as of July 2018
|
Table 1.13-5
|
Registration information of topramezone in Chile, as of July 2018
|
Table 1.13-6
|
Registration information of topramezone in China, as of July 2018
|
Table 1.13-7
|
Registration information of topramezone in Australia, as of July 2018
|
Table 1.13-8
|
Registration information of topramezone in Greece, as of July 2018
|
Table 2.1-1
|
Patent information of chlorantraniliprole in some countries/regions, as of July 2018
|
Table 2.1-2
|
Registration information of chlorantraniliprole in China, as of July 2018
|
Table 2.1-3
|
Registration information of chlorantraniliprole in Canada, as of July 2018
|
Table 2.1-4
|
Registration information of chlorantraniliprole in France, as of July 2018
|
Table 2.1-5
|
Registration information of chlorantraniliprole in the Netherlands, as of July 2018
|
Table 2.1-6
|
Registration information of chlorantraniliprole in Australia, as of July 2018
|
Table 2.1-7
|
Registration information of chlorantraniliprole in Switzerland, as of July 2018
|
Table 2.1-8
|
Registration information of chlorantraniliprole in South Africa, as of July 2018
|
Table 2.1-9
|
Registration information of chlorantraniliprole in Greece, as of July 2018
|
Table 2.2-1
|
Patent information of flubendiamide in some countries/regions, as of July 2018
|
Table 2.2-2
|
Registration information of flubendiamide in Argentina, as of July 2018
|
Table 2.2-3
|
Registration information of flubendiamide in Australia, as of July 2018
|
Table 2.2-4
|
Registration information of flubendiamide in South Africa, as of July 2018
|
Table 2.2-5
|
Registration information of flubendiamide in Chile, as of July 2018
|
Table 2.2-6
|
Registration information of flubendiamide in China, as of July 2018
|
Table 2.2-7
|
Registration information of flubendiamide in Uruguay, as of July 2018
|
Table 2.3-1
|
Patent information of metofluthrin in some countries/regions, as of July 2018
|
Table 2.3-2
|
Registration information of metofluthrin in Australia, as of July 2018
|
Table 2.3-3
|
Registration information of metofluthrin in Canada, as of July 2018
|
Table 2.3-4
|
Registration information of metofluthrin in China, as of July 2018
|
Table 2.3-5
|
Registration information of metofluthrin in the Netherlands, as of July 2018
|
Table 2.3-6
|
Registration information of metofluthrin in South Africa, as of July 2018
|
Table 2.4-1
|
Patent information of pyrifluquinazon in some countries/regions, as of July 2018
|
Table 2.5-1
|
Patent information of spirotetramat in some countries/regions, as of July 2018
|
Table 2.5-2
|
Registration information of spirotetramat in Argentina, as of July 2018
|
Table 2.5-3
|
Registration information of spirotetramat in Australia, as of July 2018
|
Table 2.5-4
|
Registration information of spirotetramat in Denmark, as of July 2018
|
Table 2.5-5
|
Registration information of spirotetramat in South Africa, as of July 2018
|
Table 2.5-6
|
Registration information of spirotetramat in Belgium, as of July 2018
|
Table 2.5-7
|
Registration information of spirotetramat in Canada, as of July 2018
|
Table 2.5-8
|
Registration information of spirotetramat in Chile, as of July 2018
|
Table 2.5-9
|
Registration information of spirotetramat in China, as of July 2018
|
Table 2.5-10
|
Registration information of spirotetramat in France, as of July 2018
|
Table 2.5-11
|
Registration information of spirotetramat in Greece, as of July 2018
|
Table 2.5-12
|
Registration information of spirotetramat in the Netherlands, as of July 2018
|
Table 2.5-13
|
Registration information of spirotetramat in Uruguay, as of July 2018
|
Table 2.5-14
|
Registration information of spirotetramat in Switzerland, as of July 2018
|
Table 2.5-15
|
Registration information of spirotetramat in Finland, as of July 2018
|
Table 2.6-1
|
Patent information of cyantraniliprole in some countries/regions, as of July 2018
|
Table 2.6-2
|
Registration information of cyantraniliprole in China, as of July 2018
|
Table 2.6-3
|
Registration information of cyantraniliprole in Canada, as of July 2018
|
Table 2.6-4
|
Registration information of cyantraniliprole in Australia, as of July 2018
|
Table 2.6-5
|
Registration information of cyantraniliprole in the Netherlands, as of July 2018
|
Table 2.6-6
|
Registration information of cyantraniliprole in Belgium, as of July 2018
|
Table 2.6-7
|
Registration information of cyantraniliprole in Argentina, as of July 2018
|
Table 2.7-1
|
Patent informulation of cyflumetofen in some countries/regions, as of July 2018
|
Table 2.7-2
|
Registration information of cyflumetofen in China, as of July 2018
|
Table 2.7-3
|
Registration information of cyflumetofen in Brazil, as of July 2018
|
Table 2.7-4
|
Registration information of cyflumetofen in Canada, as of July 2018
|
Table 2.7-5
|
Registration information of cyflumetofen in the Netherlands, as of July 2018
|
Table 2.7-6
|
Registration information of cyflumetofen in Belgium, as of July 2018
|
Table 2.7-7
|
Registration information of cyflumetofen in Argentina, as of July 2018
|
Table 3.1-1
|
Patent information of amisulbrom in some countries/regions, as of July 2018
|
Table 3.1-2
|
Registration information of amisulbrom in Belgium, as of July 2018
|
Table 3.1-3
|
Registration information of amisulbrom in France, as of July 2018
|
Table 3.1-4
|
Registration information of amisulbrom in Finland, as of July 2018
|
Table 3.1-5
|
Registration information of amisulbrom in the Netherlands, as of July 2018
|
Table 3.1-6
|
Registration information of amisulbrom in Switzerland, as of July 2018
|
Table 3.1-7
|
Registration information of amisulbrom in Australia, as of July 2018
|
Table 3.2-1
|
Patent information of fenpyrazamine in some countries/regions, as of July 2018
|
Table 3.2-2
|
Registration information of fenpyrazamine in Australia, as of July 2018
|
Table 3.2-3
|
Registration information of fenpyrazamine in Chile, as of July 2018
|
Table 3.2-4
|
Registration information of fenpyrazamine in Denmark, as of July 2018
|
Table 3.2-5
|
Registration information of fenpyrazamine in Belgium, as of July 2018
|
Table 3.2-6
|
Registration information of fenpyrazamine in France, as of July 2018
|
Table 3.2-7
|
Registration information of fenpyrazamine in the Netherlands, as of July 2018
|
Table 3.2-8
|
Registration information of fenpyrazamine in Finland, as of July 2018
|
Table 3.2-9
|
Registration information of fenpyrazamine in Switzerland, as of July 2018
|
Table 3.3-1
|
Patent information of fluopicolide in some countries/regions, as of July 2018
|
Table 3.3-2
|
Registration information of fluopicolide in Argentina, as of July 2018
|
Table 3.3-3
|
Registration information of fluopicolide in Australia, as of July 2018
|
Table 3.3-4
|
Registration information of fluopicolide in South Africa, as of July 2018
|
Table 3.3-5
|
Registration information of fluopicolide in Belgium, as of July 2018
|
Table 3.3-6
|
Registration information of fluopicolide in Brazil, as of July 2018
|
Table 3.3-7
|
Registration information of fluopicolide in Canada, as of July 2018
|
Table 3.3-8
|
Registration information of fluopicolide in Chile, as of July 2018
|
Table 3.3-9
|
Registration information of fluopicolide in China, as of July 2018
|
Table 3.3-10
|
Registration information of fluopicolide in Finland, as of July 2018
|
Table 3.3-11
|
Registration information of fluopicolide in France, as of July 2018
|
Table 3.3-12
|
Registration information of fluopicolide in the Netherlands, as of July 2018
|
Table 3.3-13
|
Registration information of fluopicolide in Switzerland, as of July 2018
|
Table 3.3-14
|
Registration information of fluopicolide in Uruguay, as of July 2018
|
Table 3.4-1
|
Patent information of isotianil in some countries/regions, as of July 2018
|
Table 3.4-2
|
Registration information of isotianil in China, as of July 2018
|
Table 3.5-1
|
Patent information of mandipropamid in some countries/regions, as of July 2018
|
Table 3.5-2
|
Registration information of mandipropamid in Belgium, as of July 2018
|
Table 3.5-3
|
Registration information of mandipropamid in Brazil, as of July 2018
|
Table 3.5-4
|
Registration information of mandipropamid in China, as of July 2018
|
Table 3.5-5
|
Registration information of mandipropamid in Canada, as of July 2018
|
Table 3.5-6
|
Registration information of mandipropamid in France, as of July 2018
|
Table 3.5-7
|
Registration information of mandipropamid in Finland, as of July 2018
|
Table 3.5-8
|
Registration information of mandipropamid in the Netherlands, as of July 2018
|
Table 3.5-9
|
Registration information of mandipropamid in Australia, as of July 2018
|
Table 3.5-10
|
Registration information of mandipropamid in Switzerland, as of July 2018
|
Table 3.5-11
|
Registration information of mandipropamid in Denmark, as of July 2018
|
Table 3.5-12
|
Registration information of mandipropamid in Chile, as of July 2018
|
Table 3.5-13
|
Registration information of mandipropamid in Argentina, as of July 2018
|
Table 3.5-14
|
Registration information of mandipropamid in South Africa, as of July 2018
|
Table 3.5-15
|
Registration information of mandipropamid in Greece, as of July 2018
|
Table 3.6-1
|
Patent information of metrafenone in some countries/regions, as of July 2018
|
Table 3.6-2
|
Registration information of metrafenone in Australia, as of July 2018
|
Table 3.6-3
|
Registration information of metrafenone in Argentina, as of July 2018
|
Table 3.6-4
|
Registration information of metrafenone in Denmark, as of July 2018
|
Table 3.6-5
|
Registration information of metrafenone in South Africa, as of July 2018
|
Table 3.6-6
|
Registration information of metrafenone in Belgium, as of July 2018
|
Table 3.6-7
|
Registration information of metrafenone in Canada, as of July 2018
|
Table 3.6-8
|
Registration information of metrafenone in Chile, as of July 2018
|
Table 3.6-9
|
Registration information of metrafenone in Switzerland, as of July 2018
|
Table 3.6-10
|
Registration information of metrafenone in France, as of July 2018
|
Table 3.6-11
|
Registration information of metrafenone in Greece, as of July 2018
|
Table 3.7-1
|
Patent information of penflufen in some countries/regions, as of July 2018
|
Table 3.7-2
|
Registration information of penflufen in Canada, as of July 2018
|
Table 3.7-3
|
Registration information of penflufen in the Netherlands, as of July 2018
|
Table 3.7-4
|
Registration information of penflufen in Australia, as of July 2018
|
Table 3.7-5
|
Registration information of penflufen in Finland, as of July 2018
|
Table 3.7-6
|
Registration information of penflufen in Belgium, as of July 2018
|
Table 3.7-7
|
Registration information of penflufen in Chile, as of July 2018
|
Table 3.8-1
|
Patent information of valifenalate in some countries/regions, as of July 2018
|
Table 3.8-2
|
Registration information of valifenalate in Belgium, as of July 2018
|
Table 3.8-3
|
Registration information of valifenalate in France, as of July 2018
|
Table 3.8-4
|
Registration information of valifenalate in Switzerland, as of July 2018
|
Table 3.8-5
|
Registration information of valifenalate in Chile, as of July 2018
|
Table 3.9-1
|
Patent information of bixafen in some countries/regions, as of July 2018
|
Table 3.9-2
|
Registration information of bixafen in Argentina, as of July 2018
|
Table 3.9-3
|
Registration information of bixafen in Australia, as of July 2018
|
Table 3.9-4
|
Registration information of bixafen in Belgium, as of July 2018
|
Table 3.9-5
|
Registration information of bixafen in Chile, as of July 2018
|
Table 3.9-6
|
Registration information of bixafen in Denmark, as of July 2018
|
Table 3.9-7
|
Registration information of bixafen in Finland, as of July 2018
|
Table 3.9-8
|
Registration information of bixafen in France, as of July 2018
|
Table 3.9-9
|
Registration information of bixafen in the Netherlands, as of July 2018
|
Table 3.9-10
|
Registration information of bixafen in South Africa, as of July 2018
|
Table 3.9-11
|
Registration information of bixafen in Switzerland, as of July 2018
|
Table 3.10-1
|
Patent information of fluopyram in some countries/regions, as of July 2018
|
Table 3.10-2
|
Registration information of fluopyram in Australia, as of July 2018
|
Table 3.10-3
|
Registration information of fluopyram in Belgium, as of July 2018
|
Table 3.10-4
|
Registration information of fluopyram in Canada, as of July 2018
|
Table 3.10-5
|
Registration information of fluopyram in China, as of July 2018
|
Table 3.10-6
|
Registration information of fluopyram in Denmark, as of July 2018
|
Table 3.10-7
|
Registration information of fluopyram in Finland, as of July 2018
|
Table 3.10-8
|
Registration information of fluopyram in France, as of July 2018
|
Table 3.10-9
|
Registration information of fluopyram in Greece, as of July 2018
|
Table 3.10-10
|
Registration information of fluopyram in the Netherlands, as of July 2018
|
Table 3.10-11
|
Registration information of fluopyram in South Africa, as of July 2018
|
Table 3.10-12
|
Registration information of fluopyram in Switzerland, as of July 2018
|
Table 3.11-1
|
Patent information of isopyrazam in some countries/regions, as of July 2018
|
Table 3.11-2
|
Registration information of isopyrazam in Argentina, as of July 2018
|
Table 3.11-3
|
Registration information of isopyrazam in Australia, as of July 2018
|
Table 3.11-4
|
Registration information of isopyrazam in Belgium, as of July 2018
|
Table 3.11-5
|
Registration information of isopyrazam in China, as of July 2018
|
Table 3.11-6
|
Registration information of isopyrazam in France, as of July 2018
|
Table 3.11-7
|
Registration information of isopyrazam in Greece, as of July 2018
|
Table 3.11-8
|
Registration information of isopyrazam in the Netherlands, as of July 2018
|
Table 3.11-9
|
Registration information of isopyrazam in Uruguay, as of July 2018
|
Table 3.12-1
|
Patent information of sedaxane in some countries/regions, as of July 2018
|
Table 3.12-2
|
Registration information of sedaxane in Argentina, as of July 2018
|
Table 3.12-3
|
Registration information of sedaxane in Australia, as of July 2018
|
Table 3.12-4
|
Registration information of sedaxane in Canada, as of July 2018
|
Table 3.12-5
|
Registration information of sedaxane in Chile, as of July 2018
|
Table 3.12-6
|
Registration information of sedaxane in China, as of July 2018
|
Table 3.12-7
|
Registration information of sedaxane in Denmark, as of July 2018
|
Table 3.12-8
|
Registration information of sedaxane in Finland, as of July 2018
|
Table 3.12-9
|
Registration information of sedaxane in France, as of July 2018
|
Table 3.12-10
|
Registration information of sedaxane in Greece, as of July 2018
|
Table 3.12-11
|
Registration information of sedaxane in Uruguay, as of July 2018
|
Table 4.1-1
|
Patent information of cyprosulfamide in some countries/regions, as of July 2018
|
Table 4.1-2
|
Registration information of cyprosulfamide in Belgium, as of July 2018
|
Table 4.1-3
|
Registration information of cyprosulfamide in Canada, as of July 2018
|
Table 4.1-4
|
Registration information of cyprosulfamide in Argentina, as of July 2018
|
Table 4.1-5
|
Registration information of cyprosulfamide in the Netherlands, as of July 2018
|